

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs)

Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
	(Unaudited) (Refer Note 2)	(Unaudited)	(Unaudited) (Refer Note 2)	(Audited)	(Audited)
Income					
Revenue from operations	97437	94942	92980	374921	345371
Other income	4068	3507	2983	14593	12259
Total Income (1+2)	101505	98449	95963	389514	357630
Expenses					
(a) Cost of materials consumed	11523	9748	20460	49990	54517
(b) Purchases of stock-in-trade	29140	16423	25574	84511	85308
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(5469)	9745	(9321)	4585	(6372)
(d) Employee benefits expense	15297	12474	17283	57970	62439
(e) Finance costs	58	9	77	131	180
(f) Depreciation and amortisation expense	1472	1880	1810	6679	6968
(g) Other expenses	13627	17360	13258	60129	58610
Total expenses	65648	67639	69141	263995	261650
Profit before exceptional items and tax (3-4)	35857	30810	26822	125519	95980
Exceptional Items [credit/ (charge)] (Refer Note 3)	-	-	240	469	(14361)
Profit before tax (5+6)	35857	30810	27062	125988	81619
Tax expense					
(a) Current tax	9015	7349	6167	32596	23759
(b) Deferred tax	555	473	1447	634	(1136)
Profit for the period/year (7-8)	26287	22988	19448	92758	58996

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025**(Rs. in Lakhs)**

Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
	(Unaudited) (Refer Note 2)	(Unaudited)	(Unaudited) (Refer Note 2)	(Audited)	(Audited)
Other comprehensive income					
(i) Items that will not be reclassified to profit or loss	(512)	157	(91)	(355)	(557)
(ii) Income tax relating to items that will not be reclassified to profit or loss	128	(39)	22	89	140
Total comprehensive income for the period (9+10)	25903	23106	19379	92492	58579
Total comprehensive income for the period attributable to owners of the Group	25903	23106	19379	92492	58579
Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941
Other equity				178190	160823
Earnings per share (EPS) (of Rs. 10 each)					
Basic and diluted EPS before Exceptional items (Rs.)	15.52	13.57	11.37	54.52	41.14
Basic and diluted EPS after Exceptional items (Rs.)	15.52	13.57	11.48	54.76	34.83
	Not Annualised				

Statement of Assets and Liabilities		Consolidated (Rs. in Lakhs)	
Particulars	As at 31.03.2025	As at 31.03.2024	
	Audited	Audited	
ASSETS			
<u>Non-Current Assets</u>			
(a) Property, Plant and Equipment	26029	27936	
(b) Right of use Assets	925	1744	
(c) Capital work-in-progress	1432	1393	
(d) Investment Property	78	92	
(e) Intangible assets	1333	2355	
(f) Financial Assets			
(i.) Other financial assets	1150	1022	
(g) Current tax assets (net)	19600	21364	
(h) Deferred tax assets (net)	14087	14631	
(i) Other non-current assets	5185	5283	
Total non-current assets	69819	75820	
<u>Current assets</u>			
(a) Inventories	48174	52505	
(b) Financial assets			
(i) Current Investments	111825	81322	
(ii) Trade receivables	29255	22206	
(iii) Cash and cash equivalents	53885	6417	
(iv) Bank balances other than (iii) above	86467	99905	
(v) Other financial assets	7078	13014	
(c) Other current assets	4305	4473	
Total current assets	340989	279842	
Total Assets	410808	355662	

Statement of Assets and Liabilities		Consolidated (Rs. in Lakhs)	
Particulars	As at 31.03.2025	As at 31.03.2024	
	Audited	Audited	
EQUITY AND LIABILITIES			
<u>Equity</u>			
(a) Equity Share Capital	16941	16941	
(b) Other Equity	178190	160823	
Total equity	195131	177764	
<u>Liabilities</u>			
<u>Non-current liabilities</u>			
(a) Financial Liabilities			
i. Lease liabilities	249	647	
ii. Other financial liabilities	-	10	
(b) Provisions	24911	24746	
Total non-current liabilities	25160	25403	
<u>Current liabilities</u>			
(a) Financial Liabilities			
i. Lease liabilities	746	1220	
ii. Trade payables			
Due to Micro Enterprises and Small Enterprises	852	198	
Due to others	69974	62343	
iii. Other financial liabilities	17702	14211	
(b) Other current liabilities	7150	5313	
(c) Provisions	41641	39352	
(d) Current tax liabilities (net)	52452	29858	
Total current liabilities	190517	152495	
Total liabilities	215677	177898	
Total equity and liabilities	410808	355662	


Statement of Cash Flows	Consolidated (Rs. in Lakhs)	
	Year ended	Year ended
	31.03.2025	31.03.2024
Particulars	Audited	Audited
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>		
Profit before exceptional items and tax	125519	95980
Adjustments for :		
Gain on disposal of property, plant and equipment (net)	151	(89)
Interest income	(7075)	(6753)
Gain on liquid investments	(6965)	(4878)
Finance costs	131	180
Depreciation and amortisation expense	6679	6968
Allowance for doubtful debts and advances	238	59
Operating Profit before working capital changes	118678	91467
<u>Change in operating assets and liabilities</u>		
Decrease/(Increase) in inventories	4331	(6508)
(Increase) in trade receivables	(7287)	(3027)
Decrease/(Increase) in other assets	5909	(1180)
Increase in trade payables	7699	19013
Increase/(Decrease) in provisions	2098	(3718)
Increase in other liabilities	5734	1521
Cash generated from operations	137162	97568
Income taxes paid (net of refunds)	(8171)	(25423)
Cash inflow from operating activities before exceptional items	128991	72145
Exceptional items :		
Payment of redundancy cost	-	(16330)
Income taxes on exceptional items	-	2385
Net cash generated from operating activities (A)	128991	58200

	Particulars	Year ended 31.03.2025	Year ended 31.03.2024
		Audited	Audited
B.	<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>		
	Payments to acquire property, plant and equipment and other intangible assets	(2302)	(3122)
	Proceeds from sale of property, plant and equipment	102	277
	Sale / redemption of mutual funds	186063	215610
	Margin money deposits (placed) / matured	1	224
	Investment in bank deposits (having original maturity more than 3 months but less than 12 months)	(329655)	(337930)
	Redemption / maturity of bank deposits (having original maturity more than 3 months but less than 12 months)	343497	350076
	Investment in mutual funds	(214348)	(242293)
	Loan given to related parties	-	(2500)
	Loan repayment from related parties	-	9500
	Advance towards sale of Property	(170)	170
	Interest received	11829	9343
	Cash outflow from investing activities before exceptional items	(4983)	(645)
	Exceptional items:		
	Proceeds from sale of property	469	1969
	Income taxes on Exceptional items	(67)	(452)
	Net cash (outflow) / inflow from investing activities (B)	(4581)	872
C.	<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>		
	Interest paid, other than on lease liabilities	(13)	(22)
	Interest paid on lease liabilities	(118)	(157)
	Principal payment of lease liabilities	(1873)	(1813)
	Dividend paid to shareholders	(74938)	(54157)
	Net cash outflow from financing activities (C)	(76942)	(56149)
	Net increase in cash and cash equivalents (A+B+C)	47468	2923
	Cash and cash equivalents at the beginning of the year	6417	3494
	Cash and cash equivalents at the end of the year	53885	6417
	<u>Net increase in cash and cash equivalents</u>	47468	2923

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th May 2025. The Statutory auditors have performed audit of the Consolidated financial results for the year ended 31st March 2025 and limited review of financial results for the quarter ended 31st March 2025 and have issued an unmodified opinion.
2. The figures for the 3 months ended 31st March 2025 and corresponding 3 months ended 31st March 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the respective financial years.
3. Exceptional items pertaining to the period / year :
(a) Exceptional items credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties and for the previous year ended 31st March 2024 of Rs. 14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
(b) Exceptional items charge for the quarter ended 31st March 2024 of Rs.240 lakhs is on account of profit on sale of surplus residential properties.
4. The Board of Directors recommend a Final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31st March 2024 Rs.32 per equity share).
5. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

13th May, 2025